Patients' attitude towards vaccination after Guillain Barré syndrome
- PMID: 34984239
- PMCID: PMC8691489
- DOI: 10.1002/hsr2.469
Patients' attitude towards vaccination after Guillain Barré syndrome
Abstract
Background and aims: Guillain Barré syndrome (GBS) could be triggered by an infectious disease but by vaccination as well. Thus, suffering GBS may influence patients' attitudes towards vaccination.
Methods: An anonymous questionnaire consisting of the Overall Neuropathy Limitations Score (ONLS), the short form-36 health survey (SF-36), and questions addressing patients' attitude towards vaccination was sent to members of a German GBS support group and to patients with GBS diagnosis who were treated at Jena University Hospital.
Results: Ninety-seven questionnaires clearly stated GBS as a diagnosis and were included in the analysis. Although 19.6% of the GBS patients reported having no disability in the long-time follow-up, a considerable number of patients still had persistent neurological symptoms; 74.2% of the GBS patients reported being able to walk at least 10 m independently. However, 5.2% were restricted to wheelchair. The patients reached lower scores in all domains of quality of life compared to German controls. Moreover, patients showed a more critical attitude towards vaccination compared to a German representative survey. Fewer patients (58.8%) received a vaccination after suffering from GBS than before (77.3%). Every tenth patient believed that vaccination was the trigger for the GBS. 32% of the patients did not receive a vaccination in the last 5 years mainly because of the fear of adverse effects (32%) or disadvise of the general practitioners (25.8%).
Discussion: Although the risk of relapse following immunization may be rather low, uncertainties and fears still impair the counseling of these patients by their medical practitioner.
Keywords: Guillain Barré syndrome; attitude; outcome; quality of life; vaccination.
© 2021 The Authors. Health Science Reports published by Wiley Periodicals LLC.
Conflict of interest statement
None of the authors has any conflict of interest to disclose.
Figures
Similar articles
-
Guillain-Barré syndrome following influenza vaccination.JAMA. 2004 Nov 24;292(20):2478-81. doi: 10.1001/jama.292.20.2478. JAMA. 2004. PMID: 15562126
-
A follow-up study on Guillain-Barre syndrome and validation of Brighton criteria.Iran J Neurol. 2019 Apr 4;18(2):64-69. Iran J Neurol. 2019. PMID: 31565202 Free PMC article.
-
Vaccine hesitancy with a history of Guillain Barre Syndrome: Weighing the risks and benefits of SARS-CoV-2 vaccination.IDCases. 2022 Mar 5;28:e01467. doi: 10.1016/j.idcr.2022.e01467. eCollection 2022. IDCases. 2022. PMID: 35284232 Free PMC article.
-
Influenza Vaccination and Guillain-Barré Syndrome: Reality or Fear.J Transl Int Med. 2019 Dec 31;7(4):137-142. doi: 10.2478/jtim-2019-0028. eCollection 2019 Dec. J Transl Int Med. 2019. PMID: 32010599 Free PMC article. Review.
-
Pharmacological treatment for pain in Guillain-Barré syndrome.Cochrane Database Syst Rev. 2013 Oct 20;(10):CD009950. doi: 10.1002/14651858.CD009950.pub2. Cochrane Database Syst Rev. 2013. PMID: 24142399 Updated. Review.
Cited by
-
Vaccine patterns among patients diagnosed with Guillain-Barré Syndrome and matched counterparts in a Medicare supplemental population, 2000-2020.Vaccine. 2023 Sep 7;41(39):5763-5768. doi: 10.1016/j.vaccine.2023.08.014. Epub 2023 Aug 10. Vaccine. 2023. PMID: 37573203
-
Adherence and Reactogenicity to Vaccines against SARS-COV-2 in 285 Patients with Neuropathy: A Multicentric Study.Brain Sci. 2022 Oct 16;12(10):1396. doi: 10.3390/brainsci12101396. Brain Sci. 2022. PMID: 36291329 Free PMC article.
-
Factors affecting the intention of COVID-19 vaccination in Korean patients with myasthenia gravis: A survey-based study.Front Neurol. 2022 Aug 5;13:847873. doi: 10.3389/fneur.2022.847873. eCollection 2022. Front Neurol. 2022. PMID: 35989937 Free PMC article.
References
-
- Shahrizaila N, Lehmann HC, Kuwabara S. Guillain‐Barré syndrome. Lancet (Lond Engl.). 2021;397(10280):1214‐1228. - PubMed
-
- Malek E, Salameh J. Guillain‐Barre Syndrome. Semin Neurol. 2019;39(5):589‐595. - PubMed
-
- McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain‐Barré syndrome worldwide. A systematic literature review. Neuroepidemiology. 2009;32(2):150‐163. - PubMed
-
- Verboon C, Doets AY, Galassi G, et al; IGOS Consortium. Current treatment practice of Guillain‐Barré syndrome. Neurology. 2019;93(1):e59‐e76. - PubMed
LinkOut - more resources
Full Text Sources
